Home / Longevity / Vesugen
VeHuman trials

Vesugen

Vesugen is a 3-amino-acid peptide (Lys-Glu-Asp, KED) from a Russian research group. It has been tested in cell cultures and in small human reports. No large trial exists.

Not approved as a drug in the US or EUOnly small human reports; no large or independent trials found
OverviewDosingMixingResearchCommunitySafetyFAQSources

Vesugen quick reference

TypeTripeptide Lys-Glu-Asp (KED)
Studied forBlood vessel cells, aging, memory
EvidenceCells, mice, small human reports
RouteHuman reports: by mouth; community: injection
Half-lifeNot established

What is Vesugen?

Three-amino-acid peptide from a Russian research group.

Used by some for circulation and vessel health.

Human evidence is small developer-run reports.

How Vesugen works

Vessel-lining cells

In cultures it raised the Ki-67 growth marker and eased endothelin-1.

Gene model

Docking suggests it fits the MKI67 gene start; unproven in people.

Sirtuin 1 (cells)

Raised sirtuin 1 in vessel-cell cultures.

Dendritic spines (mice)

KED prevented spine loss in Alzheimer's-model mouse neurons.

What Vesugen is studied for

PeopleErectile dysfunction, 41 men

Blood flow in penile arteries improved after Vesugen (2014).

PeopleAging, 32 people

Vesugen showed a larger slowing of biological aging than Pinealon, per authors.

PeopleMemory in older adults

Oral KED reported to improve memory and attention (2021 review, no numbers).

Lab / cellsAtherosclerosis cells

Eased raised endothelin-1 in diseased vessel-cell cultures.

AnimalsAlzheimer's mice

KED kept dendritic spines in mouse neurons.

Vesugen dosing protocol

ItemWhat the sources show
Human doseNot established
Route in human reportsBy mouth
Amounts in human reportsNot stated in the papers I could read
Studied inCell cultures and small human reports

Human reports come from a 2015 gerontology study and a 2021 review of KED. ClinicalTrials.gov lists no Vesugen trial (searched 5 Nov 2026).

HUMAN REPORTSOral; amounts not statedTrial
COMMUNITY RANGE500–2,000 mcg dailyCommunity
COMMUNITY CYCLE10–30 daysCommunity

Label and trial amounts come from the sources below. Community amounts are what people report; they have not been tested.

Mixing

Vial10 mg
+
BAC water2 mL
=
Strength5 mg per mL

Example math only. At 5 mg per mL, 1 mg = 0.2 mL.

Open the peptide calculator

What the research found

Small human reports. No effect sizes are given in the abstracts:

32People aged 41 to 83 in a study of Vesugen and Pinealon; Vesugen showed the larger slowing of biological aging by the authors' measures
ElderlyA 2021 review says oral KED improved memory and attention in older people with brain function problems (no numbers given)
41Men with vasculogenic erectile dysfunction; penile artery blood flow improved after Vesugen (abstract mentions no control group)

Adv Gerontol 2015 (PMID 26390612); Bull Exp Biol Med 2021 (PMID 34173097).; Adv Gerontol 2014 (PMID 25051774).

Vesugen community experience

What users report. Not tested in trials.

Positive reports

  • Warmer limbs Some feel warmer hands and feet and lighter legs.
  • Exercise tolerance Steadier stamina is reported.
  • Less swelling A few mention less leg swelling or heaviness.
  • Repeat courses Satisfied users return for short repeat courses.

Negative & mixed

  • Nothing noticed Some see no change in a short cycle.
  • Mixed causes Big circulation claims often involve other products.
  • Side complaints Headache, flushing, dizziness or injection irritation.

Vesugen stacking

Vesugen + GHK-Cu

Vessel focus plus broader tissue repair idea. Untested.

Vesugen + Pinealon

Both tested in one 32-person study; Vesugen showed more effect.

Vesugen + Epitalon

Vessel plus circadian aging idea. No synergy shown.

Vesugen side effects & safety

Common

  • No large safety trial exists.
  • Headache (community).
  • Flushing or dizziness (community).
  • Injection-site irritation (community).

Less common

  • 2015 study: more oxidant signs and fewer CD34+ blood cells.
  • Long-term injectable safety: not studied.
  • Effects with clotting disorders: unknown.

Precautions

  • Heart disease, high blood pressure or clotting disorders: see a clinician.
  • Blood thinners, antiplatelets, BP drugs, vasodilators: use caution.
  • Avoid in pregnancy and breastfeeding.
  • Avoid with peptide or vial-ingredient allergy.

Our verdict on Vesugen

Coherent vessel-cell research but small developer-run human reports. Injectable dose and long-term safety are unsourced.

Vesugen FAQ

Does Vesugen improve circulation?

One 41-man study saw better penile artery flow. It is small and developer-run.

Is Vesugen the same as KED?

Yes. Lys-Glu-Asp, the same tripeptide.

Is Vesugen approved?

No. Not approved as a drug in the US or EU.

Can it be injected?

Human reports used it by mouth. Injection is community use.

Sources

  • Effect of synthetic peptides on aging in polymorbidity patients. Adv Gerontol 2015, PMID 26390612
  • Peptide KED and neurogenesis in Alzheimer's disease. Bull Exp Biol Med 2021, PMID 34173097
  • Vasoprotective peptide KED in atherosclerosis. Adv Gerontol 2016, PMID 28539025
  • ClinicalTrials.gov search by intervention name, run 5 Nov 2026: 0 results
  • Vezugen in vasculogenic erectile dysfunction (41 patients). Adv Gerontol 2014, PMID 25051774
  • Vesugen, D-7 and Ki-67 in vascular endothelial cells. Adv Gerontol 2014, PMID 25051766
  • Neuroprotective effects of tripeptide epigenetic regulators (EDR, KED) in Alzheimer's mice. Pharmaceuticals 2021, PMID 34071923
  • Community reports summarised from public peptide-community notes (peptideprotocols.app page); user reports, not research